Von Hippel-Lindau (VHL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 Von Hippel-Lindau (VHL) disease is a rare tumor syndrome of autosomal dominant inheritance involving multiple organ systems. The genetic alteration responsible for this syndrome is a mutation in both of the alleles of the VHL gene located on the third chromosome's short arm. VHL syndrome patients inherit a single parental mutant VHL allele alone and develop the disease when a second wild copy is disabled or lost. VHL syndrome is a rare genetic disorder distinguished by the fluid-filled visceral cyst and benign tumor in various organ systems with a propensity for malignant transformation. Central nervous system (CNS) hemangioblastomas, neuroendocrine tumors, pheochromocytomas, retinal angiomas, middle ear tumors, and renal cell carcinomas (RCC) are some of the most prevalent VHL-linked tumours.

·       The worldwide prevalence is between 1.5 to 2.5 cases in 36,000 to 91,000 population. Central nervous system involvement is reported in 21% to 72% of VHL patients.

Thelansis’s “Von Hippel-Lindau (VHL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Von Hippel-Lindau (VHL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Von Hippel-Lindau (VHL) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Von Hippel-Lindau (VHL) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Von Hippel-Lindau (VHL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032